About Us
About Taiwan Exosome Co., Ltd.
Taiwan Exosome Co., Ltd. was established in 2021, dedicated to the horizontal and vertical development of novel drugs using human, animal, and plant exosomes. The company conducts in-depth scientific research and development in exosome industry technology, utilizing the most professional knowledge, equipment, and advanced technology as the foundation. It focuses on developing treatments for difficult-to-treat diseases, including autoimmune diseases and sarcopenia. Taiwan Exosome also aims to establish a "Pharmaceutical-Grade Exosome Industry Technology Platform," which includes modules for exosome separation, purification, identification, and mass production technology, making it a leader across the upstream, midstream, and downstream regenerative medical industry chain.
Research Team
Our research team is led by Dr. Chuang Yin-Ching, the first person in Taiwan to obtain information on the COVID-19 virus. He is also the former director of Liuying Chi Mei Hospital and a renowned infectious disease expert. He oversees scientific and fundamental medical research and collaborates with Dr. Chen Zhen-Xing who is a leading figure in the medical field, a medical doctor from Johns Hopkins University, and a senior advisor at the WHO South Europe Collaboration Center.
The team also includes researchers from the Liuying Chi Mei Hospital Laboratory, the laboratory of department of Biochemical Science and Technology at National Taiwan University’s College of Life Science, dozens of authoritative medical professionals from around the world (including the United States, Canada, and China), senior scientific experts, and experienced scholars dedicated to advancing research.
Chi-Chang Hong Physician Master of Medicine
Chairman, Taiwan Exosome Co., Ltd.
Former Legislator
Bachelor of Medicine, Taipei Medical University
Master of Public Health, National Taiwan University
Master of Medicine, Toronto Community Medicine Institute, Canada
Specialist, Taiwanese Society of Psychiatry
Third Chairman, Taiwan Strait Exchange Foundation
Chairman, Tatung Medical & Health Co., Ltd.
Chairman, Fuhua Electronics Co., Ltd.
About Japan Exosome Co., Ltd.
（Japan Exosome Co., Ltd.）
Japan Exosome Co., Ltd. was established on July 9, 2025, with its headquarters located at 5F, Baifaru Building Nihonbashi, 1-14-4 Bakurocho, Chuo-ku, Tokyo.
The company was jointly founded by Taiwan Exosome Corporation (TEC) and Toyota Holdings Co., Ltd., combining Taiwan’s cutting-edge exosome research and Japan’s rigorous manufacturing systems. It is dedicated to exosome technology development, regenerative medicine applications, biopharmaceutical research, and the promotion of health and beauty products.
By pioneering exosome innovation, the company aims to open a new era in regenerative medicine and health technology. With Japan as its Asia-Pacific hub, it connects markets across Europe, the United States, and Southeast Asia, promoting exosomes as the next-generation core biotechnology and establishing a new model of regenerative medicine that originates in Asia and expands globally.
Company Information
Company Name: Japan Exosome Co., Ltd.
Established: July 9, 2025
Location: 5F, Baifaru Building Nihonbashi, 1-14-4 Bakurocho, Chuo-ku, Tokyo
Main Business: Exosome technology development, regenerative medicine applications, biopharmaceutical research, and promotion of health and beauty products
Chen Zhenxing Physician, M.D.
Chairman, Japan Exosome Co., Ltd.
MD, Taipei Medical University
Master's in Clinical Medicine, Pediatrics, Kaohsiung Medical University
Master of Public Health, Johns Hopkins University, USA
Doctor of Medicine, Johns Hopkins University, USA
Senior Advisor, WHO South Europe Cooperation Center
Former Counselor, UNESCO, Paris, France
Student and collaborator of Dr. Ferid Murad, Nobel Laureate in Physiology or Medicine, 1998
Co-founder, Taiwan Exosome Biotech Co., Ltd.
Founding Chairman, Taiwan Exosome Association